Abstract
M alaria is endemic to Indonesia, particularly in the eastern part of the Health Research (Riskesdas) showed 1 Since based combination therapy (ACT) as the first line antimalarial, instead of chloroquine due to increased chloroquine resistance. Since then, the recommended ACT used in Indonesia has been the non fixed-dose for uncomplicated falciparum malaria. 2 Clinical adults, as well as children.
Some studies also reported good efficacy with falciparum malaria, with [6] [7] [8] for Plasmodium falciparum Plasmodium vivax. 1 Another possibility is that a greater number of antimalarial drugs are administered as a consequence of the non fixed-dose drug combination. Currently, treatment, as well as patient compliance in children under 15 years of age with uncomplicated malaria.
Methods
We conducted a cross-sectional study as a part of resistance in subjects with Plasmodium falciparum and Plasmodium vivax malaria in Kalimantan and health centers in Kalimantan (West and Central) and Sulawesi (North and Central). Subjects were under 15 years of age with uncomplicated P. falciparum, P. vivax or mixed malaria infection (all clinically and parasitologically confirmed), and met the inclusion consent.
All subjects were treated with a single dose of and 2). Artesunate dosage was 4mg/kg body weight/ weight/day. All subjects were followed-up three times 28 where clinical complaints after drug administration and to record this information daily on a case record parents/guardians to obtain their knowledge, attitude, and practice of ACT use, and subjects' compliance to ACT treatment.
Results

Plasmodium falciparum
Plasmodium vivax falciparum-vivax mixed infection ( Table 1) . treatment course. One subject with a falciparumvivax mixed infection was lost to follow-up. At least On calculation, the mean dosages of artesunate and Table 2 ).
recommended dosage. Compare to those studies, we found in a study prior to lower than that of adult malaria subjects in the same study. 12 one subject dropped out from the study due to loss to follow-up. 12 Complaints frequently reported during the were similar to malaria clinical symptoms. In addition, clinical complaints such as pruritus and percentage of subjects with clinical complaints continued decreasing at subsequent days of followtreatment were reportedly higher in children infected with P. vivax, compared to complaints in subjects with P. falciparum or falciparum-vivax mixed infection. Symptoms seemed to be more prominent in vivax malaria in children compared to falciparum malaria, although symptoms rarely resulted in complications or fatalities. 15, 16 administration were similar to the symptoms of malaria since we did not record clinical symptoms before we did not use laboratory studies to look for other ACT tablets taken by children, based on body weight, day of amodiaquine. These amounts were assumed medication, despite experiencing clinical complaints. Clinical complaints were managed by symptomatic sweetened tea to the children. Children with uncomplicated malaria experienced which were able to be tolerated. Clinical complaints of treatment. Subjects' compliance to treatment was the treatment course.
